The following commentary comes from an independent investor or market observer as part of TheStreet's guest contributor program, which is separate from the company's news coverage.
NEW YORK (
L'Oreal (PINK:LRLCY) is going to launch a new range of anti-aging creams in 2012 starting with the European and the U.K. market.
It faces stiff competition from
(EL - Get Report) in the prestige anti-aging beauty market. Anti-aging today forms the bulk of the facial skin care market, which itself is the largest beauty segment.
Trefis price estimate of $23
implies an upside of about 10% to the current market price.
See full analysis for L'Oreal
Europe and the U.S. together control more than 60% of the global anti-aging cosmetics market share. The market is expected to be dominated by the cosmeceutical segment growing at a CAGR of around 10%, with popular brands like Clinique developed by Estee Lauder and Allergan.
According to Global Industry Analysts, the U.S. market for anti-aging products is expected to grow from around $80 billion in 2011, of which skin care is around $20 billion, to $115 billion by 2015. The fastest growing target segment of the anti-aging market is expected to be 25- to 35- year olds who are progressively more interested in anti-aging products, especially topical skin treatments that are applied directly in the skin.
L'Oreal's anti-aging products in Europe face stiff competition from Estee Lauder, a leading market player in the prestige anti-aging category. Estee Lauder is scheduled to launch
its first global anti-age product
-- Revitalizing Supreme Global Anti-Aging Creme - that is designed specifically for European women, in February 2012.
Global anti-age, a fast-growing segment under anti-aging beauty products, refers to a single, complete product that can treat multiple signs of skin aging at one time.
to find out how a company's products impact its stock price at Trefis.
Like our charts? Embed them in your own posts using the
Trefis Wordpress Plugin
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts